I

an Read blinked.

In an unexpected about-face, Pfizer agreed to defer substantial price hikes that went into effect just last week on more than 40 medicines after its chief executive spoke with President Trump, who is under increasing pressure to take action to lower the cost of prescription drugs.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Is this the new dance craze of summer 2018?
    “The political two-step”

    I think Trump must have talked aggressive action against pharma pricing strategy after the missed 2-week deadline following his veiled threat about
    ‘voluntary action, or else’ (regulatory heavy boots).

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy